Dose Dependent Long-term In Vivo Remission of AML1/ETO Positive Acute Myeloid Leukemia with G-CSF

By Zomas A.   Stefanoudaki-Sofianatou K.   Fisfis M.   Anagnostopoulos N.I.  

Hematology, Vol. 9, Iss. 2, 2004-04 ,pp. : 107-111

Maney Publishing

Access to resources Recommend Favorite

Meningioma 1 (MN1) expression: Refined risk stratification in acute myeloid leukemia with normal cytogenetics (CN-AML)

By Aref Salah   Ibrahim Lamiaa   Morkes Hana   Azmy Emad   Ebrahim Maha  

Hematology, Vol. 18, Iss. 5, 2013-09 ,pp. : 277-283

Maney Publishing

Access to resources Recommend Favorite

The Expression Pattern of the AML1 Gene in Non-Hodgkin's B-Cell Lymphomas and Normal B Lymphocytes

By Chimienti G.   Alaibac M.   Marzullo F.   Carbone A.   Pepe G.  

Blood Cells, Molecules, and Diseases, Vol. 26, Iss. 3, 2000-06 ,pp. : 186-192

Academic Press

Access to resources Recommend Favorite

Requirement of transcription factor AML1 in proliferation of developing thymocytes

By Sato T.   Ito R.   Nunomura S.   Ohno S.-i.   Hayashi K.   Satake M.   Habu S.  

Immunology Letters, Vol. 89, Iss. 1, 2003-10 ,pp. : 39-46

Elsevier

Access to resources Recommend Favorite

CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age

By Heuvel-Eibrink Marry   Holt Bronno   Burnett Alan   Knauf Wolfgang   Fey Martin   Verhoef Gregor   Vellenga Edo   Ossenkoppele Gert   Löwenberg Bob   Sonneveld Pieter  

Annals of Hematology, Vol. 86, Iss. 5, 2007-05 ,pp. : 329-337

Springer Publishing Company

Access to resources Recommend Favorite